Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer

Lecia V. Sequist, Jhanelle Elaine Gray, Wael A. Harb, Ariel Lopez-Chavez, Robert C. Doebele, Manuel R. Modiano, David Michael Jackman, Maria Quintos Baggstrom, Akin Atmaca, Enriqueta Felip, Mariano Provencio, Manuel Cobo, Bambang Adiwijaya, Geoffrey Kuesters, Walid S. Kamoun, Karen Andreas, J. Marc Pipas, Sergio Santillana, Byoung Chul Cho, Keunchil ParkFrances A. Shepherd

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer'. Together they form a unique fingerprint.

Nursing and Health Professions

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology